Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept™ Immunotherapy to Kill Activated...
16 December 2014 - 5:09AM
Business Wire
Macrophage Therapeutics, a newly created business unit of
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), hosted a
conference where data was presented using Manocept™ platform
compound, tilmanocept, that was generated by independent academic
collaborators with expertise in the HIV/AIDS, cancer,
tuberculosis (TB), rheumatoid arthritis and cardiovascular disease
therapeutic areas. The technical presentations highlighted
tilmanocept’s ability to target activated macrophages implicated in
pathology. Specifically data were presented in:
1. Kaposi’s Sarcoma cells from human tumor extracts that contain
tumor associated macrophages (TAM’s) and are often infected with
HIV. Data demonstrated that a generic anticancer agent that has no
direct activity vs. HIV, conjugated to tilmanocept killed the
CD-206 positive TAM’s.
2. Tilmanocept labeled with a fluorescent reporter demonstrated
a high degree of co-localization with tuberculosis-associated
activated macrophages, which express CD-206, from TB granulomas
extracted from human and primate tissue.
3. Rheumatoid Arthritis (RA) - Data presented indicated that
tilmanocept containing a florescent reporter molecule demonstrates
selective localization solely into rheumatoid affected joints in a
whole live animal model of RA.
Michael McGrath, M.D., Ph.D., Professor, University of
California, San Francisco, School of Medicine, presented data from
patient tumor extracts that demonstrated highly selective killing
of only the CD206 positive cells, e.g., the tumor associated
macrophages. Dr. McGrath discussed ongoing studies designed to
further elucidate the tilmanocept conjugates effects on the tumor
cells and its contents. “This is an approach that would be
predicted to effectively target the long-lived HIV reservoirs
resistant to all current anti-viral therapies,“ said Dr.
McGrath.
Data presented by Frederick O. Cope, Ph.D., Senior Vice
President and Chief Scientific Officer of Navidea, generated with
colleagues Drs. Larry Schlesinger, Thomas Rosol and Wael Jarjour
from The Ohio State University, demonstrated the ability of
tilmanocept, conjugated to a generic active agent, to eliminate
tuberculosis from TB-infected macrophages at levels significantly
lower than currently clinically required. This suggests that
targeting activated macrophages may improve the therapeutic index
of existing narrow therapeutic index drugs. In addition, it
suggests the potential utility of using tilmanocept, linked to
other active agent(s), to broadly regulate activated
macrophages.
Data presented by Steven Grinspoon, M.D., Professor of Medicine
at Harvard Medical School highlighted the potential for a targeted
agent to activated macrophages in cardiovascular disease.
“Atherogenesis is a macrophage-driven process and strategies to
image and target activated macrophages in vulnerable plaque would
be a significant advance in the field. Data presented by the other
presenters at this meeting were encouraging, and suggests that
tilmanocept is a promising compound to explore in cardiovascular
disease,” said Dr. Grinspoon.
Navidea director Michael M. Goldberg, M.D., who is leading
Navidea’s Macrophage Therapeutics efforts, commented, “the data
presented today will shortly be enhanced by data from ongoing
studies to further advance this novel immunotherapy approach. We
are in the process of assembling a world class Scientific Advisory
Board that will assist in guiding our research further. We look
forward to regularly updating the market with new developments,
potential partnerships and results from our ongoing studies.”
About Macrophage Therapeutics
Macrophage Therapeutics, a newly created business unit of
Navidea Biopharmaceuticals, Inc., is developing new therapeutics
based on its proprietary CD206 targeting technology platform. This
will represent a new paradigm in the treatment of disease.
Depending on the active agent(s) attached to the Manocept™ backbone
as well as other core molecule permutations, it may be possible to
approach immunotherapy in a completely novel manner. This approach
has the potential to provide for management and modification of
diseases that include the immediate involvement of macrophages, the
biological products of macrophages, or the effective impact of
macrophages or their progenitor and/or daughter elements. Thus,
Macrophage Therapeutics’ Manocept platform is designed to
specifically address a key element, macrophage interactions, in the
natural progression of clinically significant diseases that impact
the lives of patients around the globe.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Macrophage TherapeuticsMichael M. Goldberg, M.D.,
201-608-5218orNavidea BiopharmaceuticalsBrent Larson,
614-822-2330Executive VP & CFO
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2024 to May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2023 to May 2024